- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02169557
Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study
June 23, 2020 updated by: Drugs for Neglected Diseases
The purpose of this study is to demonstrate the treatment success of fexinidazole, at one year follow-up visit, in HAT stage 1 and early stage 2 patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Primary Objective
-To demonstrate that the success rate of fexinidazole at one year follow-up in stage 1 and early stage 2 patients is greater than 80%. An 80 % success rate is considered as unacceptable.
Secondary Objectives
- To verify whether the success rate of fexinidazole treatment depends on the stage of the disease (stage 1 versus early stage 2); and, if the difference between the 2 stages is significant, to show that the success rate is greater than 80% and compatible with the historical success rate of NECT in early stage 2 patients and with the historical success rate of pentamidine in stage 1 patients.
- To verify whether the success rate of fexinidazole treatment depends on the number of WBCs in CSF before treatment initiation.
- To assess changes in the success rate over time.
- To evaluate the safety of fexinidazole and determine whether its safety profile is comparable to the historical safety profile of pentamidine.
Study Type
Interventional
Enrollment (Actual)
230
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kinshasa, Congo, The Democratic Republic of the
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years and older (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed informed consent
- 15 years old or more
- Male or female
- Ability to ingest at least one complete meal per day (or at least one Plumpy'Nut® sachet)
- Karnofsky index > 50
- Presence of trypanosomes in blood or lymph
- Absence of trypanosomes in CSF
- Permanent address and ability to comply with the follow-up visit schedule
- Patient agreeing to be hospitalized to receive the treatment
Exclusion Criteria:
- Severely malnutrition, defined as BMI < 16.
- Inability to take oral medication.
- Pregnancy or breastfeeding (a urine pregnancy test will be performed in all women of childbearing age within 24 h prior to treatment).
- Clinically relevant medical condition other than HAT that, in the Investigator's opinion, may jeopardize patient safety or interfere with participation in the study, including but not limited to significant liver or cardiovascular disease, documented or suspected active infection (including AIDS), CNS trauma or seizure disorders, coma or altered consciousness.
- Severely deteriorated general condition, e.g. cardiovascular shock, respiratory distress syndrome, or terminal illness.
- Any medical condition (except HAT specific symptoms) hindering communication with the Investigator as required for the completion of this study.
- Any contraindication to imidazole products (known hypersensitivity to imidazoles).
- History of HAT treatment in the past 2 years.
- Patients previously enrolled in the study or having already received fexinidazole.
- Expected follow-up difficulties (migrants, refugees, itinerant vendors, etc.).
- Current alcohol or drug abuse.
- Clinically significant abnormal laboratory value, such as:
- Alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) > 2 times ULN
- Total bilirubin (TBIL) > 1.5 times ULN
- Severe leukopenia (< 2000/mm3)
- Potassium (K+) < 3.5 mmol/L
- Any clinically significant abnormal value (see details in Investigator Manual)
- Pregnancy confirmed by a positive urine pregnancy test obtained within 24 h prior to start of study treatment (see Section 5.8.3 Contraception; p35) QTcF ≥ 450 ms as measured automatically (if the first measurement is abnormal, a second assessment will be done at least 10-20 min later, with the patient in resting position)
- Patients not tested for malaria and/or not treated adequately for this infection
- Patients not treated adequately for soil-transmitted helminthic diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Fexinidazole
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Outcome (success or failure) at the test of cure (ToC) visit 12 months after the end of treatment (EOT).
Time Frame: 12 months after end of treatment (day 11)
|
12 months after end of treatment (day 11)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Success or failure at each visit between the End of treatment and 18 months visit.
Time Frame: End of treatment (day 11) to last follow-up visit (18 months)
|
End of treatment (day 11) to last follow-up visit (18 months)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: From signature of informed consent to 18 months Follow up visit
|
|
From signature of informed consent to 18 months Follow up visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 30, 2014
Primary Completion (ACTUAL)
October 9, 2016
Study Completion (ACTUAL)
April 25, 2017
Study Registration Dates
First Submitted
May 15, 2014
First Submitted That Met QC Criteria
June 19, 2014
First Posted (ESTIMATE)
June 23, 2014
Study Record Updates
Last Update Posted (ACTUAL)
June 24, 2020
Last Update Submitted That Met QC Criteria
June 23, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DNDiHATFEX005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human African Trypanosomiasis (HAT)
-
Drugs for Neglected DiseasesCompletedHuman African Trypanosomiasis (HAT)Congo, The Democratic Republic of the
-
Drugs for Neglected DiseasesCompletedSleeping Sickness | Human African Trypanosomiasis (HAT)Central African Republic, Congo, The Democratic Republic of the, Congo
-
Drugs for Neglected DiseasesInstitute of Tropical Medicine, Belgium; Institut National de Recherche Biomédicale... and other collaboratorsNot yet recruitingHuman African Trypanosomiasis
-
Drugs for Neglected DiseasesSanofiCompletedHuman African TrypanosomiasisFrance
-
Institute of Tropical Medicine, BelgiumCompletedHuman African TrypanosomiasisCongo, The Democratic Republic of the
-
Drugs for Neglected DiseasesSwiss Tropical & Public Health Institute; Ministry of Public Health, Democratic...Completed
-
Institut de Recherche pour le DeveloppementInstitute of Tropical Medicine, Belgium; Institut National de Recherche Biomédicale... and other collaboratorsCompletedSleeping Sickness | Human African Trypanosomiasis | Trypanosoma Brucei Gambiense; Infection | African Trypanosomiases | West African Sleeping Sickness | Trypanosomiasis; African, Due to Trypanosoma Brucei Gambiense, GambienseCongo, The Democratic Republic of the, Côte D'Ivoire, Burkina Faso
-
Institut de Recherche pour le DeveloppementFoundation for Innovative New Diagnostics; Programme National de lutte contre... and other collaboratorsCompletedSleeping Sickness | Human African Trypanosomiasis | Trypanosoma Brucei Gambiense; Infection | West African Sleeping SicknessCôte D'Ivoire, Guinea
-
Foundation for Innovative New Diagnostics, SwitzerlandMakerere University; Ministry of Public Health, Democratic Republic of the...WithdrawnHuman African Trypanosomiasis
-
Institut de Recherche pour le DeveloppementInstitute of Tropical Medicine, Belgium; Institut National de Recherche Biomédicale... and other collaboratorsCompletedTrypanosoma Brucei Gambiense; Infection | Sleeping Sickness; West African | African Trypanosomiases | West African; TrypanosomiasisCongo, The Democratic Republic of the, Côte D'Ivoire, Guinea
Clinical Trials on Fexinidazole
-
SanofiCompletedHepatic Function AbnormalBulgaria, France
-
Drugs for Neglected DiseasesSanofiCompletedPK in Healthy VolunteersFrance
-
Drugs for Neglected DiseasesCompletedTrypanosomiasis, AfricanFrance
-
Drugs for Neglected DiseasesSanofiCompletedTrypanosomiasis, African | Sleeping Sickness | Trypanosomiasis; GambianCongo, The Democratic Republic of the, Guinea
-
Drugs for Neglected DiseasesCompletedHuman African Trypanosomiasis (HAT)Congo, The Democratic Republic of the
-
Drugs for Neglected DiseasesSanofiCompletedHuman African TrypanosomiasisFrance
-
Drugs for Neglected DiseasesEuropean and Developing Countries Clinical Trials Partnership (EDCTP)CompletedTrypanosoma Brucei Rhodesiense; InfectionMalawi, Uganda
-
Drugs for Neglected DiseasesTerminatedVisceral LeishmaniasisSudan
-
Drugs for Neglected DiseasesTerminated
-
Drugs for Neglected DiseasesCompletedChagas' Disease (Chronic) NosSpain